Nerve Growth Factor Market Report 2025

The nerve growth factor (NGF) market size has grown strongly in recent years. It will grow from $1.11 billion in 2024 to $1.2 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth observed during the historic period can be attributed to factors such as the rising incidence of traumatic brain injuries, the increasing prevalence of neurodegenerative diseases, greater investments in research and development, heightened awareness of nerve regeneration therapies, and a growing incidence of peripheral neuropathy.

The nerve growth factor (NGF) market size is expected to see strong growth in the next few years. It will grow to $1.63 billion in 2029 at a compound annual growth rate (CAGR) of 8%. The growth during the forecast period can be attributed to the rising demand for biopharmaceuticals, an increase in the prevalence of autoimmune neurological disorders, a greater focus on neuroinflammation research, rising investments in AI-driven drug discovery, and growing consumer demand for NGF-based therapies. Key trends expected during the forecast period include advancements in biotechnology, personalized medicine strategies, innovative drug delivery systems, regulatory approvals, and the development of NGF antibodies.

The rising prevalence of neurological disorders is expected to drive the growth of the nerve growth factor (NGF) market. Neurological disorders, which impact the brain, spinal cord, and nerves, are caused by structural, biochemical, or electrical abnormalities. The growing prevalence of these disorders is mainly attributed to aging populations and advancements in diagnostic technologies. These technological improvements enhance the detection and reporting of neurological disorders, leading to a higher documented incidence. NGF plays a vital role in the maintenance, survival, and regeneration of neurons, making it essential for addressing neurological conditions by promoting neural repair and potentially slowing disease progression. For example, in September 2024, the Australian Institute of Health and Welfare projected that dementia cases in Australia would increase from approximately 411,100 in 2023 to 849,300 by 2058. As a result, the increasing prevalence of neurological disorders is contributing to the expansion of the NGF market.

Companies in the NGF market are focused on developing advanced products, such as NGF monoclonal antibodies, to inhibit NGF and provide effective pain relief. These monoclonal antibodies are biological drugs designed to target and neutralize NGF, blocking its interaction with receptors to reduce pain and inflammation in nerves. This approach helps regulate pain signaling and supports nerve cell survival. For instance, in February 2022, Akeso, Inc., a China-based biopharmaceutical company, introduced AK115, a humanized IgG1 monoclonal antibody. This antibody received approval from China's National Medical Products Administration to begin clinical trials for pain treatment, including cancer-related pain. AK115 works by blocking NGF’s interaction with receptors, aiming to offer long-term, non-addictive pain relief, particularly for opioid-resistant cancer patients, thus enhancing their quality of life.

In June 2023, Dompé Farmaceutici, an Italy-based company known for developing the first recombinant human nerve growth factor, partnered with FarmaMondo Group to expand access to Oxervate (cenegermin). Through this partnership, FarmaMondo became the exclusive distributor of Oxervate in certain countries, making it more accessible for patients with neurotrophic keratitis outside the U.S., Canada, Italy, China, and Switzerland. FarmaMondo Group, a Switzerland-based pharmaceutical services provider, specializes in offering care services for rare diseases. This collaboration helps broaden access to NGF treatments for those in need.

Major players in the nerve growth factor market are Pfizer Inc., AstraZeneca Plc, Eli Lilly & Company, Teva Pharmaceutical Industries, Regeneron Pharmaceuticals Inc., Genetech, Dompé farmaceutici S.p.A., Promega Corporation, Akeso Inc, CUSABIO TECHNOLOGY LLC, Staidson Beijing BioPharmaceuticals, Biocare Medical LLC, Beike Biotechnology, Enzo Life Sciences Inc., Genexis Biotech Pvt. Ltd., Mimetogen Pharmaceuticals, Alomone Labs, MimeTech Srl, Herantis Pharma, Prospec-Tany Technogene Ltd., PainCeptor Pharma.

Asia-Pacific was the largest region in the nerve growth factor market in 2024. The regions covered in nerve growth factor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the nerve growth factor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Nerve growth factor (NGF) is a protein crucial for the growth, maintenance, and survival of nerve cells, particularly sensory and sympathetic neurons. It plays an essential role in the development of the nervous system and supports the regeneration of nerve cells following injury. NGF binds to specific receptors on nerve cells, activating pathways that aid in cell survival and differentiation.

The main types of nerve growth factors include alpha-nerve growth factor (NGF), beta-nerve growth factor (NGF), gamma-nerve growth factor (NGF), and others. Alpha-NGF is a protein vital for the growth and survival of neurons, as well as the development of the peripheral nervous system. It encompasses various agents, such as cenegermin, used for conditions such as neurodegenerative disorders, spinal cord injuries, eye disorders, epithelial diseases, tissue healing, and more. These treatments are distributed through multiple channels, including hospital pharmacies, online pharmacies, and retail pharmacies, and are utilized by a range of end users, including hospitals, home care settings, specialty clinics, and others.

The nerve growth factor market research report is one of a series of new reports that provides nerve growth factor market statistics, including the nerve growth factor industry global market size, regional shares, competitors with the nerve growth factor market share, detailed nerve growth factor market segments, market trends, and opportunities, and any further data you may need to thrive in the nerve growth factor industry. This nerve growth factor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nerve growth factor market consists of sales of nerve growth factor protein supplements, nerve growth factor enriched cell culture media, nerve growth factor biomarker detection kits, and diagnostic assays. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.